Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new ...
Nuvo Research Inc. (TSX:NRI), a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of ...
MISSISSAUGA, ON, Nov. 8 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through ...
Wakefield Express on MSN
Latest applications submitted to Wakefield Council: Pub to be revamped
The following applications were validated the week beginning Monday, February 2.
Nuvo Research Inc. has announced that the United States Patent Office has granted U.S. Patent No. 8,435,568, relating to compositions and methods of using WF10 and new derivative formulations for the ...
MISSISSAUGA, ON, Nov. 11 /CNW/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results